As more states legalize, your portfolio could smoke the competition.
Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.
Double-digit growth in first quarter earnings may give stocks their next big move to the upside.
Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.
Pfizer launched a Remicade biosimilar in November.
The company said in January it was looking at potential strategic options for the diabetes care business.
Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.
Goldman Sachs and Bank of America release earnings on Tuesday.
JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.
OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.
A few important takeaways from our daily Facebook show with Jim Cramer.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Incyte INCY shares.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said reports of Apple developing a diabetes testing product is not a reason to own the stock.
Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.
Some recent high-flying biotechs may be preparing for their next surge.